Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine

Amin Esmailian; Sara Laura Barnes; Marsus Pumar

doi:10.1016/j.jacig.2024.100339

Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine

J Allergy Clin Immunol Glob. 2024 Sep 6;3(4):100339. doi: 10.1016/j.jacig.2024.100339. eCollection 2024 Nov.

Authors

Amin Esmailian¹, Sara Laura Barnes^{1

2

3}, Marsus Pumar³

Affiliations

¹ Faculty of Medicine, Monash University, Melbourne, Australia.
² Monash Lung Sleep Allergy and Immunology, Clayton, Australia.
³ Monash Health, Clayton, Australia.

Abstract

We present a case of secondary T-cell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID-19 vaccination. The condition was partially managed with omalizumab after initial first-line therapy proved ineffective.

Keywords: COVID-19 vaccine; Secondary T-cell deficiency; autoimmune-induced lymphopenia; chronic spontaneous urticaria; idiopathic total lymphopenia; omalizumab.

Publication types

Case Reports